Less than a month after it agreed to sell its South San Francisco HeartScan center, Imatron has found a buyer for two of its remaining three facilities. The South San Francisco ultrafast CT developer signed an agreement March 22 with Newport Beach,
Less than a month after it agreed to sell its South San Francisco HeartScan center, Imatron has found a buyer for two of its remaining three facilities. The South San Francisco ultrafast CT developer signed an agreement March 22 with Newport Beach, CA-based firm Vital Imaging Companies for the sale of its Houston and Washington, DC, coronary artery disease risk-assessment centers. Imatron expects the sale to close by March 31.
Imatron sold the South San Francisco center Feb. 25 to Imaging Technology Group, also of South San Francisco, for $1.5 million in cash (SCAN 3/17/99). The sale represented a shift in Imatron's corporate strategy: Rather than trying to sell the HeartScan subsidiary whole, the company decided to sell each center individually.
Vital Imaging Companies includes Vital Imaging, a California firm that is not related to 3-D workstation developer Vital Images of Minneapolis. Vital Imaging intends to establish a network of facilities in major cities across the U.S., and plans to open a center this August in San Diego, according to Richard King, chairman and CEO. Vital Imaging would like to expand the scope of service at its centers to include full-body scans and open MRI, King said.
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Study Shows Enhanced Diagnosis of Coronary Artery Stenosis with Photon-Counting CTA
July 10th 2025In a new study comparing standard resolution and ultra-high resolution modes for patients undergoing coronary CTA with photon-counting detector CT, researchers found that segment-level sensitivity and accuracy rates for diagnosing coronary artery stenosis were consistently > 89.6 percent.
FDA Expands Approval of MRI-Guided Ultrasound Treatment for Patients with Parkinson’s Disease
July 9th 2025For patients with advanced Parkinson’s disease, the expanded FDA approval of the Exablate Neuro platform allows for the use of MRI-guided focused ultrasound in performing staged bilateral pallidothalamic tractotomy.